

## Australia's Telix spins off Rhine Pharma to expand global access to radiopharmaceuticals

23 October 2024 | News

**Rhine Pharma formed following a collaboration between Telix and Heidelberg University Hospital**



Australia-based Telix Pharmaceuticals has announced the spin-off of Rhine Pharma, which has the mission of expanding global access to innovative radiopharmaceuticals for cancer imaging and treatment using two generator-produced isotopes, technetium-99m ( $^{99m}\text{Tc}$ ) and rhenium-188 ( $^{188}\text{Re}$ ).

Rhine Pharma was formed following a collaboration between Telix and Heidelberg University Hospital (UKHD), which aimed to develop a PSMA-targeting small molecule that could be labelled with either  $^{99m}\text{Tc}$  for SPECT imaging, or  $^{188}\text{Re}$  for radioligand therapy.

The collaboration successfully created a potential next-generation theranostic compound, RHN001, which Rhine Pharma is now advancing into a novel Phase I/IIa theranostic clinical study (the '*RHINO Trial*'), exploring the safety profile and efficacy of both  $^{99m}\text{Tc}$ -RHN001 and  $^{188}\text{Re}$ -RHN001 in patients with advanced prostate cancer.

Because  $^{99m}\text{Tc}$  and  $^{188}\text{Re}$  can each be produced using on-site generators, they enable a highly-differentiated solution for regions with limited radiopharmaceutical manufacturing infrastructure or dispersed populations.  $^{99m}\text{Tc}$  enables imaging of patients with widely available SPECT scanners, while  $^{188}\text{Re}$  has demonstrated potential as a therapeutic isotope, thanks to its high-energy beta emission that maximises damage to tumour cells. Its short half-life (16.9 hours) also has the potential to simplify patient workflows in busy treatment centres with high patient demand or limited nuclear waste management capabilities.